KTOV News and Press, Kitov Pharma Ltd. From 05/06/20

TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreem...

Nano cap Kitov Pharma (NASDAQ: KTOV ) is down  13%  premarket on average volume in reaction to its announcement of warrant exercises to buy 20M ADSs at $0.325. Gross proceeds should be ~$6.5M. More news on: Kitov Pharma Ltd, Healthcare stocks news, Stocks on the move, Read ...

TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced a transaction resulting in expected g...

TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public o...

Kitov Pharma ( KTOV -21.1% ) announces that its manufacturing partners have completed the packaging, release and shipment of Consensi (amlodipine and celecoxib) to its marketing partners ahead of the planned U.S. commercial launch in May. More news on: Kitov Pharma Ltd, Healthcare stoc...

Company’s marketing partner s in the U.S. plan to commence selling Consensi in May 2020 Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through 2022 TEL AVIV, Israel, March 12, 2020 (GLOB...

TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced pricing of a public offering of 20,000,0...

Kitov Pharma ( KTOV +5.6% ) announces plans to expand the  Phase 1/2 clinical trial of NT-219 with cetuximab trial in patients with recurrent or metastatic head and neck cancer to also include evaluation of NT-219 as monotherapy treatment in patients with advanced solid tumors. More...

Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer Company to Present Details of Planned Phase 1/2 Trial and Preclinical...

TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today provided a corporate update and announced financial...